[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Akros Pharma Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100611952",false,"NCT07247266","Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)","A Phase 1b, Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)","Inclusion Criteria:\n\n* Diagnosed with familial cold autoinflammatory syndrome (FCAS) or Muckle-Wells syndrome (MWS) confirmed by:\n* Clinical History: At least 2 typical clinical symptoms (e.g., urticarial skin rash, myalgia, arthralgia, recurrent fever, fatigue\u002Fmalaise, conjunctivitis or other autoinflammatory symptoms) prior to the Screening Visit; AND\n* Genetic Confirmation: Confirmed nucleotide-binding and oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) mutation;\n* Willing to discontinue current anti-interleukin (IL)-1 treatment, if applicable;\n* Demonstrates de novo flaring of CAPS during the Screening Period.\n\nExclusion Criteria:\n\n* Has chronic infantile neurologic cutaneous articular syndrome (CINCA)\u002Fneonatal-onset multisystem inflammatory disease (NOMID);\n* Has a history or presence of amyloidosis, progressive hearing loss, organ damage or any symptom contraindicating anti-IL-1 treatment washout;\n* Has active systemic bacterial, fungal or viral infection(s) within 14 days prior to Day 1 or a history of clinically significant recurrent infectious diseases","ALL","18 Years","80 Years",{"count":19,"type":20},5,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)",[26],"Cryopyrin-associated Periodic Syndromes (CAPS)",[28,29,30,31,32,33,34],"JTE-162","Efficacy","Safety","Tolerability","Cryopyrin-associated periodic syndromes","CAPS","Pharmacokinetics","RECRUITING","2026-02-05",{"date":38,"type":39},"2026-02-09","ACTUAL",{"date":41,"type":39},"2026-02-02",{"date":43,"type":20},"2026-12",{"name":45,"class":46},"Akros Pharma Inc.","INDUSTRY",""]